Post-Thrombotic Syndrome, Iliocaval Obstruction, Venous Compression, and Deep Venous Reconstruction

56.1Separate acute DVT prevention from chronic disease

The first decision is temporal. Acute proximal DVT management is aimed at preventing embolism, recurrence, and later venous morbidity while keeping bleeding risk acceptable; chronic post-thrombotic syndrome is a later clinical state, not simply the fact that a patient once had a clot. The Villalta framework keeps this boundary practical: post-thrombotic syndrome is defined by a score of 5 or more on two separate occasions at least 3 months after DVT, and severe post-thrombotic syndrome by a score of 15 or more. PTS 2016 That definition prevents a common error in venous practice—treating early post-DVT swelling as if it were established scarred iliocaval obstruction. ESVS 2022

Acute anticoagulation details belong primarily in VTE prevention, diagnosis, and acute lower-extremity DVT, but the boundary matters here because it determines which operation, if any, is being considered. For eligible acute proximal DVT patients without active cancer, contemporary guidance favours a direct oral anticoagulant rather than parenteral therapy bridged to a vitamin K antagonist; in selected unprovoked proximal DVT patients with acceptable bleeding risk, extended anticoagulation is favoured over a fixed short course. Antithrombotic Therapy VTE 2021 Those choices are acute VTE decisions. They do not by themselves diagnose chronic obstruction, and they do not substitute for delayed symptom scoring and venous assessment. Editor's Choice European 2021

Catheter-directed or pharmacomechanical thrombus removal should not be offered reflexively to every patient with proximal DVT. ATTRACT randomized 692 patients with acute proximal DVT to pharmacomechanical catheter-directed thrombolysis plus anticoagulation or anticoagulation alone; at 24 months, overall post-thrombotic syndrome was not reduced, while major bleeding increased from 0.3% to 1.7%. ATTRACT 2017 The bedside lesson is not that thrombus removal has no role, but that a broad proximal-DVT population is too heterogeneous for routine lysis as a prevention strategy.

The acute iliofemoral subgroup is the reason the lysis discussion remains alive, and it should be kept in that acute lane. In the ATTRACT iliofemoral analysis, pharmacomechanical thrombus removal reduced moderate-to-severe post-thrombotic syndrome at 24 months and improved venous-disease-specific quality-of-life measures, but it still did not reduce overall post-thrombotic syndrome and carried bleeding risk. ATTRACT 2019 CaVenT, which enrolled acute first-episode iliofemoral DVT and used conventional catheter-directed thrombolysis, showed a larger 5-year post-thrombotic syndrome reduction; CAVA, using ultrasound-accelerated catheter-directed thrombolysis, did not show a statistically significant 12-month post-thrombotic syndrome reduction and was underpowered after slow enrollment. CAVA trial ultrasound-accelerated 2020 · CaVenT year post-thrombotic 2016

For the surgeon, the practical separation is this: acute iliofemoral thrombus removal is a time-sensitive discussion about fresh clot, symptom duration, limb severity, and bleeding risk; chronic post-thrombotic disease is a later discussion about symptoms, Villalta severity, venous hypertension, inflow, outflow, and whether reconstruction is likely to improve function. PTS 2016 Acute trial results should not be converted into a rationale for late lysis of scarred obstruction, nor should chronic reconstruction be presented as if it were the same treatment tested in acute-DVT thrombolysis trials. Thrombolysis acute deep 2016 · ATTRACT 2017

56.2Iliofemoral disease has a separate intervention lane

Iliofemoral venous disease deserves its own decision pathway because the anatomic level changes morbidity, technical feasibility, and the plausibility of benefit. In acute DVT, the intervention question is whether a carefully selected patient with iliofemoral involvement, short symptom duration, and acceptable bleeding risk should be considered for catheter-directed or pharmacomechanical thrombus removal. The 2016 thrombolysis review reported reduced post-thrombotic syndrome and improved clot clearance but increased bleeding, with the most clinically plausible benefit concentrated in iliofemoral cohorts rather than unselected proximal DVT. Editor's Choice European 2021 · Thrombolysis acute deep 2016

Chronic iliocaval or iliofemoral obstruction is a different clinical problem. The patient usually presents with persistent swelling, venous claudication, pain, skin change, ulceration, or functional limitation after the acute event has passed. Severe symptomatic chronic post-thrombotic iliocaval or iliofemoral obstruction that remains troublesome despite conservative care may be evaluated for venous stenting or, less commonly, open or hybrid reconstruction. The Society of Interventional Radiology position statement supports endovascular stent placement as a management option in chronic iliofemoral venous obstruction, while the broader stenting literature remains dominated by observational data rather than large randomized trials. SIR 2023 · ESVS 2022 · Editor's Choice-- Systematic 2016

The indication is never “there is a narrowed iliac vein” by itself. The stenting decision should require concordance among symptoms, chronic venous hypertension, lesion location, inflow quality, outflow target, and the patient’s goals. Historical deep venous outflow series established the clinical appeal of restoring iliac outflow in chronic venous disease, and contemporary venous-stent studies such as the ABRE pivotal experience support modern device-based treatment in symptomatic iliofemoral outflow obstruction. Pivotal Study Evaluating 2022 · Stenting venous outflow 2007 These data justify evaluation in selected patients, but they do not justify indiscriminate stenting for mild symptoms or incidental imaging findings. SIR 2023

Non-thrombotic iliac vein lesions, including the syndrome often described as May-Thurner, require the same discipline. Iliac compression is common on imaging, and the 2024 VIVA Foundation, American Venous Forum, and American Vein and Lymphatic Society consensus frames treatment around a symptomatic non-thrombotic iliac vein lesion rather than anatomy alone. AVF 2024 A patient with disabling unilateral swelling, venous claudication, pelvic or lower-limb venous hypertension features, and a concordant iliac lesion is different from an asymptomatic patient whose cross-sectional scan happens to show iliac vein compression.

Open or hybrid deep venous reconstruction is selected rather than routine. It may enter the discussion when symptoms are severe, obstruction or reflux anatomy is not adequately addressed by standard endovascular treatment, and the patient understands the uncertainty of the evidence base. Deep venous reflux correction and other reconstructive procedures have been reported in heterogeneous series and reviews, but they should be presented as specialized operations for carefully selected patients, not as default treatment for chronic venous insufficiency. ESVS 2022 · Systematic review meta-analysis 2023

56.3Planning tests must answer a treatment question

Testing should begin with the decision that will change management. In the acute setting, the decision is whether the patient remains in anticoagulation-based care or is a carefully selected acute iliofemoral intervention candidate. In chronic disease, the decision is whether symptoms meet a post-thrombotic or non-thrombotic iliac lesion threshold, whether conservative treatment has failed, and whether the anatomy is suitable for iliocaval or iliofemoral reconstruction. SIR 2023 · Antithrombotic Therapy VTE 2021 · Editor's Choice European 2021

Villalta scoring is a bedside follow-up discipline, not merely a trial endpoint. PTS 2016 A score of 5 or more on two separate occasions at least 3 months after DVT establishes post-thrombotic syndrome, and a score of 15 or more identifies severe disease. Repeating the score gives the team a shared language for judging whether the patient is improving with compression and medical care, whether symptoms are disproportionate to superficial disease, and whether chronic deep venous imaging is warranted. ESVS 2022

Advanced imaging before chronic venous reconstruction should define the treatment plan rather than merely confirm that a lesion exists. Duplex ultrasound can identify reflux, obstruction signals, residual thrombotic change, and alternative diagnoses, but iliocaval planning often requires cross-sectional venous imaging and intraprocedural assessment to define the obstructed segment, landing zones, inflow, and outflow. The VIDIO study supports the practical point that intravascular ultrasound can change stenting decisions compared with venography in iliofemoral venous obstruction; therefore IVUS is most useful when the team is already asking whether and how to reconstruct. SIR 2023 · Venography versus intravascular 2017

For non-thrombotic iliac vein lesions, imaging should be interpreted through the clinical syndrome. The 2024 VIVA/AVF/AVLS consensus supports a symptom-led approach: the diagnosis should integrate clinical presentation, exclusion of competing causes, and lesion assessment rather than relying on compression percentage alone as an automatic trigger for stenting. AVF 2024 This is especially important in day-to-day practice, because treating an incidental compression can expose a patient to permanent metal, surveillance, and antithrombotic decisions without a clear venous-hypertension target.

The acute thrombolysis trials should not be allowed to blur chronic imaging decisions. ATTRACT, CaVenT, and CAVA studied recent acute thrombus in defined trial populations; they did not test late thrombolysis for scarred post-thrombotic obstruction. CAVA trial ultrasound-accelerated 2020 · ATTRACT 2017 · CaVenT year post-thrombotic 2016 A patient with established post-thrombotic syndrome should therefore be evaluated for chronic outflow reconstruction, conservative optimization, or alternative causes of symptoms—not routed into delayed lysis because acute iliofemoral trials showed selected signals. ATTRACT 2019

Evidence uncertainty should be part of the imaging conversation. Endovenous stenting for chronic iliac obstruction is supported by consensus statements, systematic reviews, and prospective device experience, but randomized evidence for angioplasty or stenting in DVT-related obstruction remains sparse and uncertain. A 2025 Cochrane review identified only two randomized trials with 134 participants; stenting may reduce secondary venous occlusion at 24 months, but certainty was very low and effects on post-thrombotic syndrome, quality of life, and adverse events were very uncertain. DVT 2025 Imaging precision should therefore sharpen selection; it should not lower the threshold for intervention in a patient whose symptoms and anatomy do not match. Editor's Choice-- Systematic 2016

56.4Clinical integration, follow-up, and evidence boundaries

Follow-up after DVT should be built around symptom trajectory, recurrence prevention, and delayed recognition of post-thrombotic disease. Compression can be used for symptom control and remains part of conservative management, but prevention claims should be stated carefully: the SOX trial did not show that routine elastic compression stockings prevented post-thrombotic syndrome after proximal DVT, while guidance documents still support compression for selected symptomatic patients and as part of PTS management. Compression stockings prevent 2014 The practical clinic question is not simply whether stockings were prescribed, but whether swelling, heaviness, pain, skin change, venous claudication, or ulceration persists despite a realistic conservative trial. PTS 2016

Anticoagulation choice and duration remain essential, but they are not the main subject of chronic reconstruction. Eligible acute DVT patients without active cancer are generally treated with a direct oral anticoagulant, and selected unprovoked proximal DVT patients may require extended anticoagulation when bleeding risk is acceptable; detailed duration decisions are addressed in VTE prevention, diagnosis, and acute lower-extremity DVT. This chapter uses those decisions to define timing: acute treatment first, then delayed assessment for chronic post-thrombotic symptoms and reconstructable obstruction when symptoms persist. Antithrombotic Therapy VTE 2021 · Editor's Choice European 2021

When intervention is being considered, the consent discussion should distinguish three separate evidence lanes. First, routine thrombus removal for all acute proximal DVT is not supported, because ATTRACT did not reduce overall post-thrombotic syndrome and increased bleeding. ATTRACT 2017 Second, selected acute iliofemoral DVT may still justify thrombus-removal discussion when symptom duration is short and bleeding risk is acceptable. Third, chronic iliocaval or iliofemoral obstruction is evaluated for stenting or reconstruction on the basis of chronic symptoms, venous hypertension, and anatomy, using chronic-obstruction guidance and stent literature rather than acute-lysis trials. SIR 2023 · ATTRACT 2019 · Pivotal Study Evaluating 2022

The most common failure mode in non-thrombotic iliac vein lesions is treating anatomy instead of disease. A visible iliac compression should lead to a structured venous assessment, not automatically to a stent. The threshold is concordance: symptoms compatible with deep venous hypertension, lesion severity and location that plausibly explain the phenotype, exclusion of competing causes, and a patient-centred expectation that restoring iliac outflow will improve function or morbidity. AVF 2024

The second failure mode is overpromising chronic reconstruction. Modern venous stents and IVUS-guided planning have made iliocaval and iliofemoral reconstruction more reproducible, and chronic outflow restoration can be clinically valuable in selected patients. Still, much of the chronic stenting and open reconstruction literature is observational, and randomized evidence remains limited or uncertain for several patient-important outcomes. The language in clinic should therefore be precise: the goal is improvement in swelling, pain, venous claudication, skin complications, or ulcer behavior in a well-selected patient, not guaranteed eradication of post-thrombotic syndrome. DVT 2025 · Systematic review meta-analysis 2023 · Venography versus intravascular 2017 · Editor's Choice-- Systematic 2016

A disciplined chronic venous reconstruction pathway has a recognisable shape. The team documents Villalta severity and functional limitation; confirms that conservative treatment has been reasonable; excludes superficial, lymphatic, cardiac, renal, medication-related, and musculoskeletal mimics when appropriate; defines the iliocaval or iliofemoral target with imaging that can guide treatment; and separates acute thrombolysis evidence from chronic reconstruction evidence in the consent discussion. PTS 2016 That approach gives the care team a safe operating principle: restore deep venous outflow when the patient’s syndrome, anatomy, and expectations align, and do not implant a stent merely because a vein looks compressed. AVF 2024 · SIR 2023